2 January 2020 |
AIM: RENE |
("ReNeuron" or the "Company")
Total Voting Rights
At 31 December 2019, the Company had 31,833,770 ordinary shares in issue, each carrying one voting right. This follows the issue of 1,500 new shares arising from the exercise of options by staff, such shares having been admitted under the Company's existing block listing arrangement.
As the Company holds no ordinary shares in treasury, the figure of 31,833,770 may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure and Transparency Rules.
ENDS
ENQUIRIES:
|
ReNeuron |
+44 (0)20 3819 8400 |
|
Olav Hellebø, Chief Executive Officer |
|
|
Michael Hunt, Chief Financial Officer
|
|
|
Buchanan (UK) |
+44 (0) 20 7466 5000 |
|
Mark Court, Tilly Abraham
|
|
|
Argot Partners (US) |
+1 212 600 1902
|
|
Stephanie Marks, Claudia Styslinger
|
|
|
Stifel Nicolaus Europe Limited |
+44 (0) 20 7710 7600 |
|
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker)
|
|
|
N+1 Singer |
+44 (0) 20 7496 3000 |
|
Aubrey Powell, James Moat, Mia Gardner (Joint Broker) |
|
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa, and for disability as a result of stroke. ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com.
